Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 13/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.45 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CDH1 | P12830 | 1/20 | 0.41 |
| ▸ | APC | P25054 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1458917 | 1.00 | NAMPT (0.47) | NAMPTCTNNB1TCF7L2HPGDMAPT | |
| SCHEMBL9949901 | 0.92 | HPGD (0.52) | NAMPTHPGDMAPTKDM4EALDH1A1 | |
| SCHEMBL1458828 | 0.92 | HPGD (0.52) | NAMPTHPGDMAPTKDM4EALDH1A1 | |
| SCHEMBL12100430 | 0.87 | NAMPT (0.47) | NAMPTCTNNB1TCF7L2HPGDMAPT | |
| SCHEMBL12100705 | 0.85 | RAB9A (0.40) | NAMPTCTNNB1TCF7L2HPGDMAPT | |
| SCHEMBL1458121 | 0.85 | HPGD (0.48) | NAMPTCTNNB1TCF7L2HPGDMAPT | |
| SCHEMBL12100757 | 0.85 | HPGD (0.48) | NAMPTCTNNB1TCF7L2HPGDMAPT | |
| SCHEMBL9950633 | 0.85 | HPGD (0.48) | NAMPTCTNNB1TCF7L2HPGDMAPT | |
| SCHEMBL1458770 | 0.85 | NAMPT (0.47) | NAMPTHPGDMAPTKDM4EALDH1A1 | |
| SCHEMBL12099969 | 0.85 | SYK (0.41) | NAMPTHPGDMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102656163-B | Suppress the heterogeneous ring compound of PASK | BIOENERGENIX (US) | 2016-01-13 | — | — | CN | claimed |
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-13 | — | — | US | claimed |
| US-11459307-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2022-10-04 | — | — | US | disclosed |
| US-20210198216-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20210198216-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC (US) | 2021-07-01 | — | — | US | disclosed |
| US-10781185-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2020-09-22 | — | — | US | disclosed |
| US-10781185-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2020-09-22 | — | — | US | disclosed |
| US-9868708-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868708-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868708-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160229815-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC | 2016-08-11 | — | — | US | disclosed |
| US-20150031679-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX, LLC | 2015-01-29 | — | — | US | disclosed |
| US-20150031679-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX, LLC | 2015-01-29 | — | — | US | disclosed |
| US-8916560-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916560-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916560-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-23 | — | — | US | disclosed |
| US-20120165318-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165318-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165318-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2011028947-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165318-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | NAMPT 544/4885CTNNB1 3515/4885TCF7L2 2955/4885 |
| US-11459307-B2 | Heterocyclic compounds for the inhibition of PASK | PASK, PDXK, PANK2 | NAMPT 544/4885CTNNB1 3515/4885TCF7L2 2955/4885 |
| US-20160229815-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | NAMPT 544/4885CTNNB1 3515/4885TCF7L2 2955/4885 |
| US-20210198216-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | NAMPT 544/4885CTNNB1 3515/4885TCF7L2 2955/4885 |
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | NAMPT 544/4885CTNNB1 3515/4885TCF7L2 2955/4885 |
| US-20150031679-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | NAMPT 544/4885CTNNB1 3515/4885TCF7L2 2955/4885 |
| US-10781185-B2 | Heterocyclic compounds for the inhibition of PASK | PASK, PDXK, PANK2 | NAMPT 544/4885CTNNB1 3515/4885TCF7L2 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.